인터루킨 36 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "인터루킨 36" in Korean language version.

refsWebsite

Global rank Korean rank

4^th place

4^th place

2^nd place

3^rd place

4,455^th place

1,231^st place

6,897^th place

6,579^th place

doi.org

dx.doi.org

“IL-36 cytokines in autoimmunity and inflammatory disease”. 《Oncotarget》 9 (2): 2895–2901. January 2018. doi:10.18632/oncotarget.22814. PMC 5788690. PMID 29416822.
“Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation”. 《The Journal of Biological Chemistry》 293 (2): 403–411. January 2018. doi:10.1074/jbc.M117.805739. PMC 5767850. PMID 29180446.
“Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity”. 《The Journal of Biological Chemistry》 286 (49): 42594–602. December 2011. doi:10.1074/jbc.M111.267922. PMC 3234937. PMID 21965679.
“IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells”. 《Blood》 120 (17): 3478–87. October 2012. doi:10.1182/blood-2012-06-439026. PMID 22968459.
“Biology of IL-36 cytokines and their role in disease”. 《Seminars in Immunology》 25 (6): 458–65. December 2013. doi:10.1016/j.smim.2013.11.003. PMID 24355486.
“Biology of IL-36 cytokines and their role in disease”. 《Seminars in Immunology》 25 (6): 458–65. December 2013. doi:10.1016/j.smim.2013.11.003. PMID 24355486.

jbc.org

“Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation”. 《The Journal of Biological Chemistry》 293 (2): 403–411. January 2018. doi:10.1074/jbc.M117.805739. PMC 5767850. PMID 29180446.

nih.gov

ncbi.nlm.nih.gov

“IL-36 cytokines in autoimmunity and inflammatory disease”. 《Oncotarget》 9 (2): 2895–2901. January 2018. doi:10.18632/oncotarget.22814. PMC 5788690. PMID 29416822.
“Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation”. 《The Journal of Biological Chemistry》 293 (2): 403–411. January 2018. doi:10.1074/jbc.M117.805739. PMC 5767850. PMID 29180446.
“Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity”. 《The Journal of Biological Chemistry》 286 (49): 42594–602. December 2011. doi:10.1074/jbc.M111.267922. PMC 3234937. PMID 21965679.
“IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells”. 《Blood》 120 (17): 3478–87. October 2012. doi:10.1182/blood-2012-06-439026. PMID 22968459.
“Biology of IL-36 cytokines and their role in disease”. 《Seminars in Immunology》 25 (6): 458–65. December 2013. doi:10.1016/j.smim.2013.11.003. PMID 24355486.
“Biology of IL-36 cytokines and their role in disease”. 《Seminars in Immunology》 25 (6): 458–65. December 2013. doi:10.1016/j.smim.2013.11.003. PMID 24355486.

unige.ch

archive-ouverte.unige.ch

“IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells”. 《Blood》 120 (17): 3478–87. October 2012. doi:10.1182/blood-2012-06-439026. PMID 22968459.